Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Share-based Compensation (2016 - 2026)

Champions Oncology has reported Share-based Compensation over the past 17 years, most recently at $423000.0 for Q1 2026.

  • For Q1 2026, Share-based Compensation rose 65.23% year-over-year to $423000.0; the TTM value through Jan 2026 reached $1.0 million, up 28.63%, while the annual FY2025 figure was $654000.0, 41.5% down from the prior year.
  • Share-based Compensation for Q1 2026 was $423000.0 at Champions Oncology, up from $249000.0 in the prior quarter.
  • Over five years, Share-based Compensation peaked at $423000.0 in Q3 2023 and troughed at $9000.0 in Q4 2024.
  • A 5-year average of $236117.6 and a median of $249000.0 in 2025 define the central range for Share-based Compensation.
  • Biggest five-year swings in Share-based Compensation: tumbled 83.02% in 2024 and later skyrocketed 2666.67% in 2025.
  • Year by year, Share-based Compensation stood at $119000.0 in 2022, then crashed by 55.46% to $53000.0 in 2023, then tumbled by 83.02% to $9000.0 in 2024, then skyrocketed by 2666.67% to $249000.0 in 2025, then skyrocketed by 69.88% to $423000.0 in 2026.
  • Business Quant data shows Share-based Compensation for CSBR at $423000.0 in Q1 2026, $249000.0 in Q4 2025, and $208000.0 in Q3 2025.